| Name | Title | Contact Details |
|---|---|---|
Nick Melrose |
VP, Health Plan Partnerships | Profile |
Kerrie Peraino |
VP, People Operations, Google Cloud | Profile |
Julia Rozovsky |
Head of People Operations, Analytics and | Profile |
Christopher Girardi |
Head of Performance Marketing | Profile |
Utpal Koppikar |
Chief Financial Officer | Profile |
SecureChart is a Baton Rouge, LA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Pharmaceutical Education & Research Institute Inc is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Elara Caring is one of the nation`s largest providers of home-based care, with a national footprint in the Northeast, Midwest and Southwest. Elara brings together three award-winning organizations – Great Lakes Caring, National Home Health Care, and Jordan Health Services – into one transformational company, which provides the highest-quality comprehensive care continuum of personal care, skilled home health, and hospice care. The company is comprised of 32,500 caregivers serving over 65,000 patients and their families daily, in 225 locations across 16 states and focused on providing our patients with the “right care, at the right time, in the right place.”
During the past 40 years, AXMINSTER Medical Group has earned the reputation as being a provider of distinctive care and service. The physicians and nurses at AXMINSTER Medical Group believe in a team approach to offering patient care. They work
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.